AlphaFold had the Protein Data Bank. The virtual cell now has consortia generating one — $500M+ in newly committed funding (CZ Biohub Virtual Biology Initiative, Apr 2026) building the open foundation atlas of cellular response.
What's still missing: mechanism on proprietary compounds, in the cell types pharma actually screens against. Open data cannot ingest pharma IP. Internal hERG and CiPA flag risk; they don't deliver mechanism. Generic CROs execute; they don't iterate.
Perturb is built to answer compound-specific cardiac safety questions for pharma drug-safety teams. Each engagement runs as a closed-loop research program in human iPSC-cardiomyocytes: AI-orchestrated experimental design, cloud-lab execution (Arctoris), multimodal mechanism profiling (Cell Painting + DRUG-seq + electrophysiology), active learning across 2–3 iterations within a 4–8 week window. NDA-protected.
The same engine extends to any molecular biology question that needs an answer fast.